Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.reuters.com/business/healthcare-pharmaceuticals/astrazeneca-buy-amolyt-pharma-105-bln-boost-rare-diseases-portfolio-2024-03-14/
https://www.globenewswire.com//news-release/2023/11/16/2781765/0/en/Amolyt-Pharma-Named-Biotech-Company-of-the-Year-at-the-LSX-European-Lifestars-Awards.html
https://www.globenewswire.com//news-release/2023/10/16/2760578/0/en/Amolyt-Pharma-Announces-Data-on-Prevalence-of-Bone-Disease-in-Patients-with-Hypoparathyroidism-and-Favorable-Bone-Effects-of-Eneboparatide-at-the-American-Society-for-Bone-and-Mine.html
https://www.globenewswire.com//news-release/2023/10/03/2753543/0/en/Amolyt-Pharma-Announces-Two-Poster-Presentations-at-the-American-Society-for-Bone-and-Mineral-Research-ASBMR-2023-Annual-Meeting.html
https://www.globenewswire.com//news-release/2023/09/27/2750298/0/en/Amolyt-Pharma-to-Present-Data-on-the-Renal-Effects-of-Eneboparatide-a-PTHR1-Agonist-in-Phase-3-for-the-Treatment-of-Hypoparathyroidism-at-the-39th-Congress-of-the-French-Society-of.html
https://www.globenewswire.com/news-release/2023/06/07/2683684/0/en/Amolyt-Pharma-to-Host-Hybrid-Key-Opinion-Leader-Event-on-Eneboparatide-a-PTHR1-Agonist-Entering-Phase-3-for-the-Treatment-of-Hypoparathyroidism-in-Chicago-on-June-16-2023.html
https://www.globenewswire.com/news-release/2023/06/05/2681897/0/en/Amolyt-Pharma-Announces-Initiation-of-Phase-1-Clinical-Trial-of-Peptide-Growth-Hormone-Receptor-Antagonist-GHRA-AZP-3813-for-Acromegaly.html
https://www.globenewswire.com/news-release/2023/06/01/2680254/0/en/Amolyt-Pharma-Launches-Public-Awareness-Campaign-to-Honor-World-Hypoparathyroidism-Awareness-Day.html
https://www.globenewswire.com/news-release/2023/05/11/2666656/0/en/Amolyt-Pharma-Announces-Oral-Presentation-at-the-25th-European-Congress-of-Endocrinology-ECE-2023.html
https://www.pharmiweb.com/press-release/2023-05-05/amolyt-pharma-announces-abstracts-accepted-for-presentation-at-ece-and-endo